NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

flipper, you wrote:

However, if Fraunhofer "optimized" DCVax-L (a bold statement by them), it is likely they broadened ALC inclusion because they thought they had a better equivalent version of DCVax-L that could handle those patients as well -- which they may have, and only validation and equivalency are holding things up.

can you repeat the link that indicated the "optimization" by Fraunhofer?
Edit: is this the link?
www.izi.fraunhofer.de/content/dam/izi/en/documents/Publications/Annual_Report_IZI_2015.pdf
Pg 34? Includes contact person Caroline Sonnabend.

Take a look here:
http://www.izi.fraunhofer.de/en/departments/leipzig-location/therapy-validation.html
and click on "PROJECTS" tab ...
includes:

Companion diagnostic for a clinical trial (Phase III) to evaluate the immunotherapeutic DCVax®-L for the treatment of Glioblastoma Multiforme
DCVax®-L (Northwest Biotherapeutics GmbH) is a therapeutic agent based on endogenous immune cells that will be used for treating Glioblastoma Multiforme after standard therapy. The treatment is based on immune cells of the peripheral blood which are differentiated in vitro to specific antigen-presenting cells, dendritic cells (DCs). The immature DCs are subsequently brought into contact with a tumor lysate, and thereby "trained" to recognize tumor cells. The maturated DCs are injected into the patient and can now trigger an immune response against remaining tumor cells. As part of a clinical trial (Phase III) to test the efficacy of DCVax®-L, cells from patients' peripheral blood (peripheral blood mononuclear cells; PBMCs) are isolated, quality controlled and cryopreserved for long-term storage. The aim of the project is to develop suitable diagnostic assays which can demonstrate a functional immune response in patients after treatment with DCVax®-L to support clinical data.

Project manager
Dr. Ulla Schwertassek

Perhaps someone could reach out to this Dr Ulla Schwertassek and obtain some info about the "optimization" they were able to achieve? Or perhaps Dr. Jörg Lehmann could shed some light?

Contact:
Dr. Jörg Lehmann
Head of Department of Therapy Validation, Head of GLP test facility

Fraunhofer Institute for Cell Therapy and Immunology IZI
Perlickstraße 1 04103 Leipzig, Germany

Phone [phone]

Email:
http://www.izi.fraunhofer.de/en/send-mail?m=1.14c7f05bdb9652cbaadc02d373a048f4&k=4ac3b67267204c65686d616e6e&r=2f656e2f6465706172746d656e74732f6c6569707a69672d6c6f636174696f6e2f746865726170792d76616c69646174696f6e2e68746d6c

Or ....................

perhaps follow this page & "Projects"
http://www.izi.fraunhofer.de/en/departments/leipzig-location/gmp-cell-and-gene-therapy.html
which includes additional contact info:

Dr. Gerno Schmiedeknecht
Head of Department of GMP Cell and Gene Therapy

Fraunhofer Institute for Cell Therapy and Immunology IZI
Perlickstraße 1 04103 Leipzig, Germany

Phone [phone]


Kati Kebbel
Dipl.-Ing. Kati Kebbel
Head of Department of GMP Cell and Gene Therapy

Fraunhofer Institute for Cell Therapy and Immunology IZI
Perlickstraße 1 04103 Leipzig, Germany

Phone [phone]